Organogenesis Reports Robust Third Quarter Growth
Company Announcements

Organogenesis Reports Robust Third Quarter Growth

Organogenesis Holdings ( (ORGO) ) has released its Q3 earnings. Here is a breakdown of the information Organogenesis Holdings presented to its investors.

Organogenesis Holdings Inc. is a leading company in the regenerative medicine sector, specializing in advanced wound care and surgical and sports medicine solutions.

In its third-quarter 2024 financial results, Organogenesis reported a net revenue of $115.2 million, marking a 6% increase compared to the same period in 2023. This growth was primarily driven by a 7% rise in the Advanced Wound Care segment, while the Surgical & Sports Medicine segment experienced a modest 1% increase.

The company achieved a net income of $12.3 million, a significant improvement from the $3.2 million recorded in the third quarter of 2023. Despite this, there was a decrease in adjusted EBITDA, which fell to $13.4 million from the previous year’s $16.0 million. Operating expenses rose by 10%, driven by an increase in selling, general, and administrative expenses.

Looking ahead, Organogenesis is projecting net revenue growth between 5% and 11% for the year ending December 31, 2024. The company remains committed to working with policymakers to address spending while ensuring access to its therapies, indicating a cautiously optimistic outlook for future growth.

Related Articles
TheFlyOrganogenesis reports Q3 EPS 9c, consensus (1c)
TheFlyOrganogenesis reports Q3 EPS 9c, consensus (1c)
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App